SCHEMBL231035

SCHEMBL231035

[CH]1CCCC12CCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25238188 0.97
SCHEMBL11777486 0.97
SCHEMBL11773212 0.97
SCHEMBL7393104 0.97
SCHEMBL19297 0.97
SCHEMBL168533 0.93
SCHEMBL165344 0.93
SCHEMBL229043 0.93
SCHEMBL217094 0.90
SCHEMBL11773209 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1683 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024140638-A1 COMPOUND BASED ON SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE-BASED ISOINDOLINONE SKELETON AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-07-04 WO claimed
WO-2024140637-A1 OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-07-04 WO claimed
US-20240109866-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2024-04-04 US claimed
WO-2024051766-A1 MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-03-14 WO claimed
WO-2024032689-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-02-15 WO claimed
WO-2024032501-A1 COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 深圳众格生物科技有限公司 2024-02-15 WO claimed
WO-2023227867-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Cerevance, Inc. (US) 2023-11-30 WO claimed
WO-2023151635-A1 COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF 标新生物医药科技(上海)有限公司 2023-08-17 WO claimed
US-20230096517-A1 GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2023-03-30 US claimed
EP-4146345-A2 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF Teon Therapeutics, Inc. (US) 2023-03-15 EP claimed
US-20230015914-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-01-19 US claimed
EP-4112614-A1 GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF Shanghaitech University (CN) 2023-01-04 EP claimed
EP-3983412-A1 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF Teon Therapeutics, Inc. (US) 2022-04-20 EP claimed
WO-2021226206-A2 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC. (US) 2021-11-11 WO claimed
EP-3802500-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-04-14 EP claimed
WO-2020251957-A1 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF TEON THERAPEUTICS, INC. (US) 2020-12-17 WO claimed
WO-2017160926-A1 ANALGESIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. (US) 2017-09-21 WO claimed
WO-2014028669-A1 NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY BIOGEN IDEC MA INC. (US) 2014-02-20 WO claimed
US-12042353-B2 Curable composition for use in a high temperature lithography-based photopolymerization process and method of producing crosslinked polymers therefrom ALIGN TECHNOLOGY, INC. (US) 2024-07-23 US disclosed
US-3989744-A STIMULATES SMOOTH MUSCLES, PROSTAGLANDINS MILES LABORATORIES, INC. (US) 1976-11-02 US disclosed